Cerebral amyloidoses: molecular pathways and therapeutic challenges
Salvatore Monaco1, Gianluigi Zanusso, Sara Mazzucco
1Section of Clinical Neurology, Department of Neurological and Visual Sciences, University of Verona, Ospedale G.B. Rossi, Piazzale L.A. Scuro, 10, I-37134, Verona, Italy. salvatore.monaco@univr.it
Current Medicinal Chemistry
|July 18, 2006
Summary
Alzheimer disease and prion diseases involve protein aggregate buildup. Novel therapies target these aggregates to modify disease progression and treat neurodegeneration.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer disease (AD) and Creutzfeldt-Jakob disease (CJD) are neurodegenerative disorders characterized by protein aggregate accumulation in the brain.
- AD involves amyloid beta (Abeta) peptide formation from amyloid precursor protein (APP).
- CJD involves prion protein (PrP(C)) misfolding into infectious PrP(Sc) isoforms.
Purpose of the Study:
- To review the molecular mechanisms underlying AD and prion diseases.
- To discuss novel therapeutic strategies targeting protein misfolding and aggregation.
Main Methods:
- Review of existing literature on AD and prion disease pathogenesis.
- Analysis of experimental and clinical data on anti-amyloid therapies.
Main Results:
- Abeta and PrP(Sc) aggregates are implicated in neuronal death in AD and prion diseases.
- Diverse physicochemical states of Abeta and PrP(Sc) contribute to disease heterogeneity.
- PrP(Sc) possesses infectious properties, raising public health concerns.
Conclusions:
- Therapeutic efforts are focused on disease-modifying, anti-amyloid strategies.
- Interventions include immunization and drugs promoting non-amyloidogenic protein processing.
- Understanding molecular mechanisms is crucial for developing effective treatments for these neurodegenerative conditions.
More Related Videos
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Cerebral Edema ll: Pathophysiology
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...